(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 June 2014 (26.06.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/096015 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *C07K 19/00* (2006.01)
C07K 16/30 (2006.01) *C07K 14/74* (2006.01)
C07K 14/705 (2006.01)

(21) International Application Number:
PCT/EP2013/077109

(22) International Filing Date:
18 December 2013 (18.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12198904.0 21 December 2012 (21.12.2012) EP
13175469.9 8 July 2013 (08.07.2013) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacher Strasse 124, CH-4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US).

(72) Inventors: **GEORGES, Guy**; Am Berggraben 11, 82392 Habach (DE). **IMHOF-JUNG, Sabine**; Egenhofenstrasse 26 b, 82152 Planegg (DE). **KNOETGEN, Hendrik**; Agathe-Fleissner-Weg 16, 82377 Penzberg (DE). **SCHMITTNAEGEL, Martina**; Luswiese 2, 82327 Tutzing (DE).

(74) Agents: **SKOLAUT, Alexander** et al.; Roche Diagnostics GmbH, Patent Department (LPP.....6164), P.O.Box 11 52, 82372 Penzberg (DE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: DISULFIDE-LINKED MULTIVALENT MHC CLASS I COMPRISING MULTI-FUNCTION PROTEINS

Figure 1



(57) Abstract: Herein is reported a disulfide-linked multivalent multi-function protein, characterized in that it comprises two or more antigen presenting domains, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a β2-microglobulin, and (ii) the extracellular domains α1, α2, and α3 of a class I MHC molecule with a relative frequency of less than 1 %, or (i) a T-cell response eliciting peptide, (ii) a β2-microglobulin, and (iii) the extracellular domains α1, α2, and α3 of a class I MHC molecule with a relative frequency of 1 % or more, wherein the antigen binding site binds to a cancer cell surface antigen or a virus-infected cell surface antigen and wherein the antigen presenting domain has at least two non-naturally occurring cysteine residues which form an intrachain/interdomain disulfide bond.

WO 2014/096015 A1